RecruitingMelanoma Stage IIIMelanoma Stage IV

Beta Glucan's Effect on Pembrolizumab Immunologic Response in Stage III-IV Melanoma

Eligible age

18+ yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

The purpose of this study is to determine how beta-glucan affects the immune system in subjects with melanoma.

Sponsor: Kelly McMasters

✓ Any patients with suspected (clinical) or definitive (tissue) diagnosis of Stage III-IV melanoma starting or continuing adjuvant Pembrolizumab without active evidence of disease (NED).
✓ Must be treatment naïve or have had treatment no less than 6 months prior to enrollment
✓ 18 years or older
✓ Must be able to take pills
✓ ECOG performance status of 0-3
✓ Ability to understand and willingness to sign a written informed consent
✓ Members of all racial and ethnic groups are eligible for this study

✕ History of hypersensitivity reactions attributed to beta-glucan
✕ Patients receiving continuous or other ongoing immunosuppressive therapy
✕ Uncontrolled intercurrent illness including, but not limited to, autoimmune diseases, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
✕ Any patients who have serious autoimmune toxicity during the study period, or those who have disease recurrence during the 6-week study period should be excluded and analyzed separately
✕ Patients with mucosal melanoma
✕ Patients with concurrent malignancy or recent history thereof

Louisville

Source: ClinicalTrials.gov · NCT04513028 · last updated 2025-10-30